LDR Holding Corp (LDRH) was Downgraded by Brean Capital to ” Hold”. Earlier the firm had a rating of “Buy ” on the company shares. Brean Capital advised their investors in a research report released on Jun 17, 2016.
Many Wall Street Analysts have commented on LDR Holding Corp. Company shares were Downgraded by Barclays on Jun 10, 2016 to ” Equal Weight”, Firm has raised the Price Target to $ 37 from a previous price target of $27 .Company shares were Downgraded by RBC Capital Mkts on Jun 9, 2016 to ” Sector Perform”, Firm has raised the Price Target to $ 37 from a previous price target of $33 .LDR Holding Corp was Downgraded by Gabelli & Co to ” Hold” on Jun 8, 2016.
On the company’s financial health, LDR Holding Corp reported $-0.26 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on May 10, 2016. Analyst had a consensus of $-0.23. The company had revenue of $42.40 million for the quarter, compared to analysts expectations of $42.84 million. The company’s revenue was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.12 EPS.
LDR Holding Corp opened for trading at $37 and hit $37.77 on the upside on Wednesday, eventually ending the session at $37.02, with a gain of 0.33% or 0.12 points. The heightened volatility saw the trading volume jump to 21,90,670 shares. Company has a market cap of $1,082 M.
In a different news, on Apr 19, 2016, Patrick Richard (EVP, European Sales, Medical) sold 25,000 shares at $27.60 per share price. According to the SEC, on Mar 11, 2016, G. Joseph Ross (Exec VP Global Marketing) sold 17,613 shares at $23.07 per share price. On Nov 12, 2015, Robert Mcnamara (Chief Financial Officer) sold 19,373 shares at $26.15 per share price, according to the Form-4 filing with the securities and exchange commission.
LDR Holding Corporation is a global medical device company. The Company is focused on designing and commercializing surgical technologies for the treatment of patients suffering from spine disorders. The Company’s primary products are based on its VerteBRIDGE fusion and Mobi non-fusion platforms both of which are designed for applications in the cervical and lumbar spine. The Company’s VerteBRIDGE products are designed around its plating technology that enables surgeons to implant VerteBRIDGE devices with direct visualization of the disc and to affix the devices to the vertebrae from inside the spinal disc space. The Company’s Mobi non-fusion platform is highlighted by Mobi-C a cervical disc replacement device with a patented mobile bearing core that is designed to replicate the natural anatomical movement of the spine by facilitating independent bending and twisting similar to a healthy disc.